The National Institutes of Health, through its NIH Guide, has recently published the following funding-related notices and funding opportunities:

General Notices

• Notice of NCIs Participation in RFA-HG-23-041 Network of Genomics-Enabled Learning Health Systems (gLHS) Clinical Sites (U01, Clinical Trial Required)
  (NOT-CA-23-087)
  National Cancer Institute

• Notice of NIGMS Informational Webinar for PAR-23-110 "Biomedical Technology Optimization and Dissemination Center (BTOD)"
  (NOT-GM-23-052)
  National Institute of General Medical Sciences

• Notice of Informational Webinar on the NIH Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Program Notices of Funding Opportunity (K99/R00 and UE5)
  (NOT-GM-23-053)
  National Institute of General Medical Sciences

• Notice of Expiration of NOT-HL-23-102 "Notice of Special Interest (NOSI): Promoting implementation research to address HIV-associated comorbidities and risk factors within well-established cohorts (R01 Clinical Trial Optional)"
  (NOT-HL-23-112)
  National Heart, Lung, and Blood Institute

• Notice Regarding Added Language for Scored Review Criteria for the Evaluation and Planning Core for RFA-OH-23-003
  (NOT-OH-23-004)
  National Institute for Occupational Safety and Health

• Request for Information (RFI): Inviting Comments and Suggestions on Updating the NIH Mission Statement
  (NOT-OD-23-163)
  National Institutes of Health

Notice of Changes to Funding Opportunities

• Notice of Change to PAR-23-021, "Avenir Award Program for Genetic or Epigenetic of Substance Use Disorders (DP1 Clinical Trial Optional)"
  (NOT-DA-23-037)
  National Institute on Drug Abuse

• Notice of Change in Eligibility to Part I for RFA-DK-23-001 "A Consortium for Gut-Brain Communication in Parkinsons Disease (U24 Clinical Trial not allowed)"
  (NOT-DK-23-030)
  National Institute of Diabetes and Digestive and Kidney Diseases

• Notice of Changes of PAR-21-314 "Blueprint MedTech: Incubator Hubs (U54 Clinical Trial Not Allowed)"
  (NOT-EB-23-016)
  National Institute of Biomedical Imaging and Bioengineering
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity for The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research (K12 Clinical Trial Optional)
  (NOT-CA-23-081)
  National Cancer Institute

• Notice of Intent to Publish a Funding Opportunity Announcement for Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional)
  (NOT-CA-23-084)
  National Cancer Institute

• Notice of Intent to Publish a Funding Opportunity Announcement for Pre-Cancer Atlas (PCA) Research Centers (U01 Clinical Trial Not Allowed)
  (NOT-CA-23-085)
  National Cancer Institute

• Notice of Intent to Publish a Funding Opportunity Announcement for Human Tumor Atlas (HTA) Research Centers (U01 Clinical Trial Not Allowed)
  (NOT-CA-23-086)
  National Cancer Institute

• Notice of Intent to Publish a Funding Opportunity Announcement for Justice Community Overdose Innovation Network - Phase II Research Hubs (U01 Clinical Trial Required)
  (NOT-DA-25-025)
  National Institute on Drug Abuse

Notices of Special Interest

• Notice of Special Interest (NOSI): Epidemiology and Prevention in Alcohol Research
  (NOT-AA-23-018)
  National Institute on Alcohol Abuse and Alcoholism
  National Cancer Institute

• Notice of Special Interest: National Center for Complementary and Integrative Health (NCCIH) T32 Supplement Program to Promote Diversity in Health Research
  (NOT-AT-24-012)
  National Center for Complementary and Integrative Health

• Notice of Special Interest (NOSI): Promoting implementation research to address HIV-associated comorbidities and risk factors within well-established longitudinal studies (R01 Clinical Trial Optional)
  (NOT-HL-23-113)
  National Heart, Lung, and Blood Institute

Funding Opportunities

• Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)
  (PA-23-263)
  National Institutes of Health
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
   
• AHRQ Improving Diagnostic Safety in Ambulatory Care: Strategies and Interventions (R18)
  (PA-23-290)
  Agency for Healthcare Research and Quality
   
• AHRQ Understanding and Improving Diagnostic Safety in Ambulatory Care: Incidence and Contributing Factors (R01)
  (PA-23-291)
  Agency for Healthcare Research and Quality
   
• Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
  (PAR-23-274)
  National Institute on Aging
   
• Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
  (PAR-23-279)
  National Cancer Institute
   
• Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
  (PAR-23-280)
  National Cancer Institute
   
• Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)
  (PAR-24-027)
  National Institute on Drug Abuse
   
• Building Neuroscience Research Infrastructure for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) in Africa (UG3/UH3 Clinical Trial Not Allowed)
  (RFA-AG-24-027)
  National Institute on Aging
   
• Chimeric Antigen Receptor (CAR) Approaches to AD/ADRD (R61/R33 Clinical Trial Not Allowed)
  (RFA-AG-24-046)
  National Institute on Aging
   
• The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed)
  (RFA-CA-23-042)
  National Cancer Institute
   
• HEAL Initiative: Justice Community Overdose Innovation Network (JCOIN) - Phase II Methodology and Advanced Analytics Resource Center (UM1 Clinical Trial Not Allowed)
  (RFA-DA-24-068)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
   
• HEAL Initiative: Justice Community Overdose Innovation Network (JCOIN) - Phase II Coordination and Translation Center (U2C Clinical Trial Optional)
  (RFA-DA-24-069)
  National Institute on Drug Abuse
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
   
• Engaging Survivors of Sexual Violence and Trafficking in HIV and Substance Use Disorder Services (R34 Clinical Trial Optional)
  (RFA-DA-25-018)
  National Institute on Drug Abuse
   
• Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R01 Clinical Trial Optional)
  (RFA-MH-24-160)
  National Institute of Mental Health
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Office of AIDS Research
  Office of Research on Women's Health
   
• Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R21 Clinical Trial Optional)
  (RFA-MH-24-161)
  National Institute of Mental Health
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Office of AIDS Research
  Office of Research on Women's Health
   
• Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R34 Clinical Trial Optional)
  (RFA-MH-24-162)
  National Institute of Mental Health
  Office of AIDS Research
  Office of Research on Women's Health
   
• Community Partnerships to Advance Science for Society (ComPASS): Health Equity Research Hubs (UC2 Clinical Trial Optional)
  (RFA-RM-23-012)
  Office of Strategic Coordination (Common Fund)
   

Members of the University of Iowa community may direct questions to the UI Division of Sponsored Programs at dsp@uiowa.edu(link sends e-mail)(link sends e-mail) or 313-335-2123, or email Ann Ricketts at ann-ricketts@uiowa.edu(link sends e-mail)(link sends e-mail) or Lynn Hudachek at lynn-hudachek@uiowa.edu(link sends e-mail)(link sends e-mail).